As a start-up strategy the Pegylatt aims to develop innovative pharmaceuticals for known targets. Pegylatt will lead the entire development from cloning to marketing without building an in-house expertise for all steps of the value chain. Extensive partnering will allow Pegylatt to leverage existing excellence. The Pegylatt will focus to design new drugs, preclinical studies and clinical trials, to work intensively in expression system construction, cell biology and protein engineering, and to manage New Drug Application (NDA) , patent matter and whole of the project, the most parts of value creation. The successful file for Inestigational New Drug of our first development project, a new PEGylated rhG-CSF, confirmed the long-term orientation of our set-up. Three further pharmaceuticals are currently under development in collaboration with our partners, the State Key Laboratory of Biochemical Engineering(Institute of Process Engineering, Chinese Academy of Sciences) and the Tianjin State Key Laboratory of Pharmacokinetics and Pharmacodynamics.Service and product we could provide as follows
Pharmaceutical grade recombinant proteins, such as rhG-CSF, rhGM-CSF, IFN alfa&beta, rhIL-2, rhIL-3, rhIL-6, TNF alfa, rPA et al. Site-specific PEGylation of recombinant proteins. Design and perform manufacturing process development for recombinant proteins. Design and perform preclinical studies and clinical trials for biotech products in China.